Meclizine – Possibly the most gatekept growth plate modulator?

oska_blnn

oska_blnn

Iron
Joined
Oct 28, 2024
Posts
202
Reputation
142
I am genuinely surprised that almost nobody here has ever brought up Meclizine in the context of skeletal growth. The entire community seems focused on GH, IGF-1, CNP analogues, and other well-known interventions, yet Meclizine appears to have slipped completely under the radar.



Mechanistically, it is fascinating. Meclizine is an old antihistamine prescribed for motion sickness, but beyond its H1 receptor blockade, it has a very specific off-target effect: it downregulates FGFR3 signaling in growth plate chondrocytes. For context, FGFR3 is the single most important negative regulator of longitudinal bone growth. High FGFR3 activity suppresses chondrocyte proliferation and hypertrophy, thereby reducing the efficiency of endochondral ossification.



By attenuating FGFR3, Meclizine essentially removes part of the “brake” on the growth plate. The implications:

• Wider proliferative zones in the physis.
• Greater hypertrophic chondrocyte size.
• Increased longitudinal growth velocity while the plates remain open.



Crucially, this has nothing to do with accelerating epiphyseal closure. That process is primarily driven by estrogen exposure and senescence within the growth plate, not FGFR3 signaling. In other words, Meclizine cannot extend the lifespan of the growth plate, but it can plausibly increase the amount of growth achieved during its remaining lifespan.



Animal models support this: in achondroplasia mouse studies, Meclizine treatment partially rescued longitudinal bone growth by counteracting overactive FGFR3. Yet, for some reason, this compound remains almost entirely unmentioned in discussions on height optimization.



I cannot help but feel that Meclizine is one of the most gatekept drugs in this space. Readily available, mechanistically sound, supported by preclinical data — yet absent from virtually every conversation. Perhaps I am among the very few drawing attention to it here, but it seems to me like an overlooked key in the growth optimization puzzle.



Has anyone else seriously considered or experimented with this? I would be very interested to hear perspectives and reasons why it’s not as good as i’m saying it is.

Chatgpt wrote it for me cuz ion wanna write but trust me y’all meclizine is fucking op :lul: please bump.
 
Last edited:
  • +1
Reactions: afkaik, Sadist, davidlaidisme67 and 7 others
gpt
 
  • +1
Reactions: aids and Wexilarious
  • JFL
  • +1
Reactions: Sadist, aids, Wexilarious and 1 other person
saar saar so high iq!
bro i’m a larper look at my profile 🤩.
meclizine is still not known tho and fucking op so shut the hell up lil vro.
 
  • JFL
Reactions: Deathninja328
bro rly said
 
I am genuinely surprised that almost nobody here has ever brought up Meclizine in the context of skeletal growth. The entire community seems focused on GH, IGF-1, CNP analogues, and other well-known interventions, yet Meclizine appears to have slipped completely under the radar.



Mechanistically, it is fascinating. Meclizine is an old antihistamine prescribed for motion sickness, but beyond its H1 receptor blockade, it has a very specific off-target effect: it downregulates FGFR3 signaling in growth plate chondrocytes. For context, FGFR3 is the single most important negative regulator of longitudinal bone growth. High FGFR3 activity suppresses chondrocyte proliferation and hypertrophy, thereby reducing the efficiency of endochondral ossification.



By attenuating FGFR3, Meclizine essentially removes part of the “brake” on the growth plate. The implications:

• Wider proliferative zones in the physis.
• Greater hypertrophic chondrocyte size.
• Increased longitudinal growth velocity while the plates remain open.



Crucially, this has nothing to do with accelerating epiphyseal closure. That process is primarily driven by estrogen exposure and senescence within the growth plate, not FGFR3 signaling. In other words, Meclizine cannot extend the lifespan of the growth plate, but it can plausibly increase the amount of growth achieved during its remaining lifespan.



Animal models support this: in achondroplasia mouse studies, Meclizine treatment partially rescued longitudinal bone growth by counteracting overactive FGFR3. Yet, for some reason, this compound remains almost entirely unmentioned in discussions on height optimization.



I cannot help but feel that Meclizine is one of the most gatekept drugs in this space. Readily available, mechanistically sound, supported by preclinical data — yet absent from virtually every conversation. Perhaps I am among the very few drawing attention to it here, but it seems to me like an overlooked key in the growth optimization puzzle.



Has anyone else seriously considered or experimented with this? I would be very interested to hear perspectives and reasons why it’s not as good as i’m saying it is.

Chatgpt wrote it for me cuz ion wanna write but trust me y’all meclizine is fucking op :lul: please bump.
the only question is does it work with normalactive fgfr3
 
I am genuinely surprised that almost nobody here has ever brought up Meclizine in the context of skeletal growth. The entire community seems focused on GH, IGF-1, CNP analogues, and other well-known interventions, yet Meclizine appears to have slipped completely under the radar.



Mechanistically, it is fascinating. Meclizine is an old antihistamine prescribed for motion sickness, but beyond its H1 receptor blockade, it has a very specific off-target effect: it downregulates FGFR3 signaling in growth plate chondrocytes. For context, FGFR3 is the single most important negative regulator of longitudinal bone growth. High FGFR3 activity suppresses chondrocyte proliferation and hypertrophy, thereby reducing the efficiency of endochondral ossification.



By attenuating FGFR3, Meclizine essentially removes part of the “brake” on the growth plate. The implications:

• Wider proliferative zones in the physis.
• Greater hypertrophic chondrocyte size.
• Increased longitudinal growth velocity while the plates remain open.



Crucially, this has nothing to do with accelerating epiphyseal closure. That process is primarily driven by estrogen exposure and senescence within the growth plate, not FGFR3 signaling. In other words, Meclizine cannot extend the lifespan of the growth plate, but it can plausibly increase the amount of growth achieved during its remaining lifespan.



Animal models support this: in achondroplasia mouse studies, Meclizine treatment partially rescued longitudinal bone growth by counteracting overactive FGFR3. Yet, for some reason, this compound remains almost entirely unmentioned in discussions on height optimization.



I cannot help but feel that Meclizine is one of the most gatekept drugs in this space. Readily available, mechanistically sound, supported by preclinical data — yet absent from virtually every conversation. Perhaps I am among the very few drawing attention to it here, but it seems to me like an overlooked key in the growth optimization puzzle.



Has anyone else seriously considered or experimented with this? I would be very interested to hear perspectives and reasons why it’s not as good as i’m saying it is.

Chatgpt wrote it for me cuz ion wanna write but trust me y’all meclizine is fucking op :lul: please bump.
Link me some of the studies proving ur point
@MyDreamIsToBe183CM
 
  • +1
Reactions: Sadist
I am genuinely surprised that almost nobody here has ever brought up Meclizine in the context of skeletal growth. The entire community seems focused on GH, IGF-1, CNP analogues, and other well-known interventions, yet Meclizine appears to have slipped completely under the radar.



Mechanistically, it is fascinating. Meclizine is an old antihistamine prescribed for motion sickness, but beyond its H1 receptor blockade, it has a very specific off-target effect: it downregulates FGFR3 signaling in growth plate chondrocytes. For context, FGFR3 is the single most important negative regulator of longitudinal bone growth. High FGFR3 activity suppresses chondrocyte proliferation and hypertrophy, thereby reducing the efficiency of endochondral ossification.



By attenuating FGFR3, Meclizine essentially removes part of the “brake” on the growth plate. The implications:

• Wider proliferative zones in the physis.
• Greater hypertrophic chondrocyte size.
• Increased longitudinal growth velocity while the plates remain open.



Crucially, this has nothing to do with accelerating epiphyseal closure. That process is primarily driven by estrogen exposure and senescence within the growth plate, not FGFR3 signaling. In other words, Meclizine cannot extend the lifespan of the growth plate, but it can plausibly increase the amount of growth achieved during its remaining lifespan.



Animal models support this: in achondroplasia mouse studies, Meclizine treatment partially rescued longitudinal bone growth by counteracting overactive FGFR3. Yet, for some reason, this compound remains almost entirely unmentioned in discussions on height optimization.



I cannot help but feel that Meclizine is one of the most gatekept drugs in this space. Readily available, mechanistically sound, supported by preclinical data — yet absent from virtually every conversation. Perhaps I am among the very few drawing attention to it here, but it seems to me like an overlooked key in the growth optimization puzzle.



Has anyone else seriously considered or experimented with this? I would be very interested to hear perspectives and reasons why it’s not as good as i’m saying it is.

Chatgpt wrote it for me cuz ion wanna write but trust me y’all meclizine is fucking op :lul: please bump.
Gray, Meclizine is an h1 receptor blockade, it has passive fgfr3 down regulations, guess when is fgfr3 high, pre pubertal u dumbfuh, dont js copy shi.
 
Last edited:
  • +1
Reactions: org3cel.RR
Gray, Meclizine is an h1 receptor blockade, it has passive fgfr3 down regulations, guess when is fgfr3 high, pre pubertal u dumbfuh, dont js copy shi.
gray calling gray gray
 
read this study, it seems promising, maybe run this with a pth analog since it looks like it might mess up bone mineral density

 
  • +1
Reactions: jeoyw9192
Has anyone actually tried it?
 
Has anyone actually tried it?
not yet but luckily its an OTC medication so if you want to abuse it you could just walk into a pharmacy
 
  • +1
Reactions: oska_blnn
not yet but luckily its an OTC medication so if you want to abuse it you could just walk into a pharmacy
Seems promising tbh I'll research it a bit more and look around for more anecdotes
 
  • +1
Reactions: kenalodaunt
I am genuinely surprised that almost nobody here has ever brought up Meclizine in the context of skeletal growth. The entire community seems focused on GH, IGF-1, CNP analogues, and other well-known interventions, yet Meclizine appears to have slipped completely under the radar.



Mechanistically, it is fascinating. Meclizine is an old antihistamine prescribed for motion sickness, but beyond its H1 receptor blockade, it has a very specific off-target effect: it downregulates FGFR3 signaling in growth plate chondrocytes. For context, FGFR3 is the single most important negative regulator of longitudinal bone growth. High FGFR3 activity suppresses chondrocyte proliferation and hypertrophy, thereby reducing the efficiency of endochondral ossification.



By attenuating FGFR3, Meclizine essentially removes part of the “brake” on the growth plate. The implications:

• Wider proliferative zones in the physis.
• Greater hypertrophic chondrocyte size.
• Increased longitudinal growth velocity while the plates remain open.



Crucially, this has nothing to do with accelerating epiphyseal closure. That process is primarily driven by estrogen exposure and senescence within the growth plate, not FGFR3 signaling. In other words, Meclizine cannot extend the lifespan of the growth plate, but it can plausibly increase the amount of growth achieved during its remaining lifespan.



Animal models support this: in achondroplasia mouse studies, Meclizine treatment partially rescued longitudinal bone growth by counteracting overactive FGFR3. Yet, for some reason, this compound remains almost entirely unmentioned in discussions on height optimization.



I cannot help but feel that Meclizine is one of the most gatekept drugs in this space. Readily available, mechanistically sound, supported by preclinical data — yet absent from virtually every conversation. Perhaps I am among the very few drawing attention to it here, but it seems to me like an overlooked key in the growth optimization puzzle.



Has anyone else seriously considered or experimented with this? I would be very interested to hear perspectives and reasons why it’s not as good as i’m saying it is.

Chatgpt wrote it for me cuz ion wanna write but trust me y’all meclizine is fucking op :lul: please bump.
btw y’all i’ll start using this soon, my paycheck arrived at the 15 of this month, i’ll let y’all know on any side effects once i start.
 
  • +1
Reactions: rizzyjizzy720
.
 
Last edited:
anything so far?
i measured my height at 5'10" (which is .5 inches taller) but i'm not sure if it's just because of morning height, i'll make sure and let you know
 
i measured my height at 5'10" (which is .5 inches taller) but i'm not sure if it's just because of morning height, i'll make sure and let you know
Sounds good appreciate it boss
 
Sounds good appreciate it boss
it’s been 14+ hours since i woke up and i didn’t go back to 5’9” so im thinking it might have actually worked
 
i measured my height at 5'10" (which is .5 inches taller) but i'm not sure if it's just because of morning height, i'll make sure and let you know
Nigga thinks it's possible he grew .5 inches in a day :lul:
 
  • JFL
Reactions: cadee and Asoka
Why not just use vosoritide
 
its a weak inhibitor it wont do shit jfl
 
I’m a gray but doesn’t overreactive fgfr3 make shorter bones also 95% of mice experiments doesn’t apply to humans. Normal puberty growth is driven by GH, IGF-1, testosterone, and nutrition not FGFR3. The last also is fgfr3 is only tested on mice with a rare fgfr3 problem
 
I’m a gray but doesn’t overreactive fgfr3 make shorter bones also 95% of mice experiments doesn’t apply to humans. Normal puberty growth is driven by GH, IGF-1, testosterone, and nutrition not FGFR3. The last also is fgfr3 is only tested on mice with a rare fgfr3 problem
humans with overactive fgfr3 ended up being shorter
 
btw y’all i’ll start using this soon, my paycheck arrived at the 15 of this month, i’ll let y’all know on any side effects once i start.
Can’t you use any antihistamines?
 
btw y’all i’ll start using this soon, my paycheck arrived at the 15 of this month, i’ll let y’all know on any side effects once i start.
Mirin tag me for updates.
 
  • +1
Reactions: CrispyJ

Users who are viewing this thread

Back
Top